Publications by authors named "M Piert"
Purpose: NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non-small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether midtreatment F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease.
View Article and Find Full Text PDFArticle Synopsis
- This clinical trial aimed to improve treatment outcomes for patients with locally advanced non-small cell lung cancer (NSCLC) by using adaptive radiation therapy that tailors the treatment based on the patient's response, while minimizing side effects like lung and esophageal toxicity.
- A total of 47 patients participated, receiving personalized radiation doses based on imaging techniques (FDG-PET and SPECT) to maximize the dose to the tumor while sparing healthy lung tissue.
- Results showed manageable toxicity levels after one year, with 21.3% experiencing grade 2 pneumonitis and 66.0% grade 2 esophagitis, while striving for better local control and overall survival.
Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed.
View Article and Find Full Text PDFObjective: To aid in the diagnosis and treatment of patients with metastatic tumor seeding, an exceedingly rare phenomenon following minimally invasive urological surgery, additional case reports are needed.
Materials And Methods: We report our experience with patients determined to have peritoneal carcinomatosis following robotic-assisted radical prostatectomy (RARP) and provide a descriptive summary of these unique cases.
Results: Five cases of peritoneal carcinomatosis were identified, all of which occurred relatively late-between 8 and 13 years-following RARP.
[Ga]Ga-PSMA-11, a urea-based peptidomimetic, is a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging that targets the prostate-specific membrane antigen (PSMA). The recent Food and Drug Administration approval of [Ga]Ga-PSMA-11 for PET imaging of patients with prostate cancer, expected follow-up approval of companion radiotherapeutics (e.g.
View Article and Find Full Text PDF